Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Reiss

Showing results (181-190 of 207) with videos related to

Pageof 21
Sort By:
AIDS (London, England)|February 10, 1998
Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapyN A Foudraine, G J Weverling, T van Gool, et al.
Human Brain Mapping|July 14, 2018
Intrinsic connectivity network dynamics in PTSD during amygdala downregulation using real-time fMRI neurofeedback: A preliminary analysisAndrew A Nicholson, Daniela Rabellino, Maria Densmore, et al.
HIV Medicine|May 21, 2014
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equationsK Petoumenos, P Reiss, L Ryom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2008
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction, C A Sabin, A d'Arminio Monforte, et al.
The Journal of Infectious Diseases|June 9, 2001
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected personsA I Veldkamp, M Harris, J S Montaner, et al.
AIDS (London, England)|August 19, 2004
Cardio- and cerebrovascular events in HIV-infected personsA d'Arminio, C A Sabin, A N Phillips, et al.
AIDS (London, England)|June 15, 2000
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individualsR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
HIV Clinical Trials|April 19, 2012
Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissueS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
Lancet (London, England)|July 31, 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyM H Reijers, G J Weverling, S Jurriaans, et al.
The Netherlands Journal of Medicine|August 29, 2015
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patientsJ E Arends, J T M van der Meer, D Posthouwer, et al.
Pageof 21

Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|February 10, 1998
Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapyN A Foudraine, G J Weverling, T van Gool, et al.
Human Brain Mapping|July 14, 2018
Intrinsic connectivity network dynamics in PTSD during amygdala downregulation using real-time fMRI neurofeedback: A preliminary analysisAndrew A Nicholson, Daniela Rabellino, Maria Densmore, et al.
HIV Medicine|May 21, 2014
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equationsK Petoumenos, P Reiss, L Ryom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2008
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction, C A Sabin, A d'Arminio Monforte, et al.
The Journal of Infectious Diseases|June 9, 2001
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected personsA I Veldkamp, M Harris, J S Montaner, et al.
AIDS (London, England)|August 19, 2004
Cardio- and cerebrovascular events in HIV-infected personsA d'Arminio, C A Sabin, A N Phillips, et al.
AIDS (London, England)|June 15, 2000
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individualsR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
HIV Clinical Trials|April 19, 2012
Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissueS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
Lancet (London, England)|July 31, 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyM H Reijers, G J Weverling, S Jurriaans, et al.
The Netherlands Journal of Medicine|August 29, 2015
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patientsJ E Arends, J T M van der Meer, D Posthouwer, et al.
Pageof 21